154 related articles for article (PubMed ID: 33146047)
21. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY
Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803
[TBL] [Abstract][Full Text] [Related]
22. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
23. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.
Grcević D; Lukić IK; Kovacić N; Ivcević S; Katavić V; Marusić A
Clin Exp Immunol; 2006 Oct; 146(1):146-58. PubMed ID: 16968409
[TBL] [Abstract][Full Text] [Related]
24. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.
Tsurukai T; Udagawa N; Matsuzaki K; Takahashi N; Suda T
J Bone Miner Metab; 2000; 18(4):177-84. PubMed ID: 10874596
[TBL] [Abstract][Full Text] [Related]
25. Expression of typical osteoclast markers by PBMCs after PEG-induced fusion as a model for studying osteoclast differentiation.
Castillo LM; Guerrero CA; Acosta O
J Mol Histol; 2017 Jun; 48(3):169-185. PubMed ID: 28343338
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
27. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.
Kim JH; Kim K; Youn BU; Jin HM; Kim N
Cell Signal; 2010 Sep; 22(9):1341-9. PubMed ID: 20466061
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms involved in enhancement of osteoclast formation by activin-A.
Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14(+) and CD14(-) cell fractions.
Costa-Rodrigues J; Fernandes A; Fernandes MH
Cell Prolif; 2011 Oct; 44(5):410-9. PubMed ID: 21951284
[TBL] [Abstract][Full Text] [Related]
30. The alarmin S100A9 hampers osteoclast differentiation from human circulating precursors by reducing the expression of RANK.
Di Ceglie I; Blom AB; Davar R; Logie C; Martens JHA; Habibi E; Böttcher LM; Roth J; Vogl T; Goodyear CS; van der Kraan PM; van Lent PL; van den Bosch MH
FASEB J; 2019 Sep; 33(9):10104-10115. PubMed ID: 31199668
[TBL] [Abstract][Full Text] [Related]
31. Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro.
Baek JM; Ahn SJ; Cheon YH; Lee MS; Oh J; Kim JY
Mol Med Rep; 2017 Feb; 15(2):784-792. PubMed ID: 28035412
[TBL] [Abstract][Full Text] [Related]
32. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.
Matsuzaki K; Udagawa N; Takahashi N; Yamaguchi K; Yasuda H; Shima N; Morinaga T; Toyama Y; Yabe Y; Higashio K; Suda T
Biochem Biophys Res Commun; 1998 May; 246(1):199-204. PubMed ID: 9600092
[TBL] [Abstract][Full Text] [Related]
33. Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes.
Shinoda K; Sugiyama E; Taki H; Harada S; Mino T; Maruyama M; Kobayashi M
Bone; 2003 Oct; 33(4):711-20. PubMed ID: 14555277
[TBL] [Abstract][Full Text] [Related]
34. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
35. Effects of vascular endothelial growth factor-C and -D on osteoclast differentiation and function in human peripheral blood mononuclear cells.
Motokawa M; Tsuka N; Kaku M; Kawata T; Fujita T; Ohtani J; Matsuda Y; Terao A; Tanne K
Arch Oral Biol; 2013 Jan; 58(1):35-41. PubMed ID: 22771550
[TBL] [Abstract][Full Text] [Related]
36. LncRNA Bmncr alleviates the progression of osteoporosis by inhibiting RANML-induced osteoclast differentiation.
Chen RS; Zhang XB; Zhu XT; Wang CS
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9199-9206. PubMed ID: 31773670
[TBL] [Abstract][Full Text] [Related]
37. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
38. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
39. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.
Zauli G; Rimondi E; Nicolin V; Melloni E; Celeghini C; Secchiero P
Blood; 2004 Oct; 104(7):2044-50. PubMed ID: 15213096
[TBL] [Abstract][Full Text] [Related]
40. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.
Miyazaki M; Fujikawa Y; Takita C; Tsumura H
Clin Rheumatol; 2007 Feb; 26(2):231-9. PubMed ID: 16586042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]